Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan/Gilead, AbbVie/MPP boost access to HIV medicines

This article was originally published in Scrip

Executive Summary

Access to Gilead Sciences's next-generation HIV medicines and pediatric formulations of AbbVie's biggest-selling antiviral therapy will increase in developing countries under new agreements with commercial and nonprofit partners, Mylan and the Medicines Patent Pool (MPP).

You may also be interested in...



Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos

Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.

Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos

Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.

Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations

Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel